[Pubmed] Immunosuppressive treatment for myasthenia gravis crises improve the taste disorder in patients with thymoma: t

[RSS-Bot]

Mediastinum. 2023 Aug 7;7:40. doi: 10.21037/med-23-8. eCollection 2023.

ABSTRACT

BACKGROUND: Taste disorders in patients with thymoma accompanied by myasthenia gravis (MG) is rare.

CASE DESCRIPTION: The first case was a male in his 50s who underwent surgery for Masaoka stage III type B3 thymoma. He experienced a loss of taste before surgery, which showed no improvement after surgery. Due to a MG crisis 44 days after surgery, the patient underwent intensive treatment with mechanical ventilation, steroid pulse therapy, and intravenous immunoglobulin (IVIG) therapy. The patient recovered taste when he started oral food intake after the treatment for the MG crisis (about 3 months after surgery). Despite the recovery of taste after steroid pulse therapy and IVIG therapy, taste disorder gradually worsened about 1 year and 9 months after surgery, resulting in an almost complete loss of sweet taste 2 years after surgery. The second case was a male in his 60s who underwent surgery for Masaoka stage II type B1 thymoma. He experienced loss of taste before surgery, which showed no improvement after surgery. Five years and two months after surgery, the patient was diagnosed with a MG crisis and underwent steroid pulse therapy. Along with improvements in MG symptoms, taste disorders gradually improved. After 6 years and 10 months of surgery, the patient is still alive without MG symptoms (only pyridostigmine, 180 mg/body/day), taste disorder, and thymoma recurrence.

CONCLUSIONS: The autoimmune mechanism may contribute to taste disorders in patients with thymoma, which can be recovered by immunosuppressive treatment in our cases.

PMID:38090033 | PMC:PMC10713234 | DOI:10.21037/med-23-8


Source: https://pubmed.ncbi.nlm.nih.gov/3809003 ... 2&v=2.18.0